NASDAQ · Biotechnology

RAPP (RAPP) Stock

$42.13 +3.55% NASDAQ: RAPP Healthcare

Valuation

MetricValue
Price$42.13
Market Cap$2.01B
P/E Ratio-8.69
P/B Ratio3.94
P/S Ratio70.89
EPS (TTM)$-4.20
52-Week High$43.54
52-Week Low$10.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-28.33%
ROA-19.10%
ROCE-25.83%
Gross Margin97.54%
Operating Margin-6.11%
Net Margin-5.36%
Debt/Equity0.02
Current Ratio26.26

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-10.0M$-36.0M$-83.0M$-125.0M
Net Profit$-11.0M$-35.0M$-78.0M$-111.0M
EPS$-0.29$-0.95$-3.78$-2.86
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$32.0M$155.0M$315.0M$512.0M
Total Liabilities$12.0M$181.0M$10.0M$28.0M
Cash$31.0M$70.0M$57.0M$53.0M
Borrowings$10.0M$2.0M$1.0M$11.0M

Latest News

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? Motley Fool · Jul 12, 2026 Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target MT Newswires · Jun 24, 2026 Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? Insider Monkey · Jun 16, 2026 Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? Simply Wall St. · Jun 8, 2026 BTIG Raises its Price Target on Rapport Therapeutics (RAPP) Insider Monkey · Jun 5, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-3.0M$-27.0M$-65.0M$-87.0M
Investing Cash Flow$-6.0M$-80.0M$-173.0M$-188.0M
Financing Cash Flow$0$0$0$0
Net Cash Flow$31.0M$39.0M$-13.0M$-4.0M
Free Cash Flow$-4.0M$-29.0M$-67.0M$-88.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-11.31
FCF Yield-5.68%
Quick Ratio27.08
Interest Coverage—
Return 1Y166.97%
Return 3Y—
Return 5Y—

Ownership

Insiders Held4.60%
Institutions Held109.58%
Institutions Float Held114.87%
Institutional HolderSharesReport Date
FMR, LLC7,168,9392026-03-31
Trv Gp V, LLC 7,135,2332026-03-31
Arch Venture Management, Llc3,728,7382026-03-31
Capital International Investors3,097,9732026-03-31
Cormorant Asset Management, LP2,957,5212026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
KOD $41.58 -2.16% -8.11 $2.60B 0.00%
MNMDMind Medicine (MindMed) Inc. $20.69 +0.44% -18.83 $1.56B 0.00%
NRIX $24.11 -0.17% -6.41 $2.50B 0.00%

About RAPP

RAPP is led by CEO Abraham N. Ceesay, publicly traded since 2024.

RAPP stock trades at $42.13 with a market capitalization of $2.01B. The stock is valued at a price-to-earnings (P/E) ratio of -8.69, price-to-book of 3.94, price-to-sales of 70.89. Over the past 52 weeks the stock has ranged between $10.51 and $43.54, and currently trades 3.2% below its 52-week high.

On profitability, RAPP generates a return on equity (ROE) of -28.33%, return on capital employed of -25.83%, an operating margin of -6.11%, a net profit margin of -5.36%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides